MO01.29 Randomized, Open-Label Study of Bintrafusp Alfa vs. Pembrolizumab as First-Line (1L) Treatment in Patients with PD-L1–Expressing Advanced Non-Small Cell Lung Cancer (NSCLC)
Year: 2021
Type: conference-abstract
Source: Journal of Thoracic Oncology
Institutions: Samsung Medical Center, Centre National de la Recherche Scientifique, Inserm, Aix-Marseille Université, Centre de Recherche en Cancérologie de Marseille, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, University of California, Los Angeles, Ronald Reagan UCLA Medical Center, Instituto Alexander Fleming, University of Chicago, Merck KGaA, Darmstadt (Germany), Merck Healthcare KGaA, Darmstadt (Germany), Hospital Universitario 12 De Octubre
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3120329586